Back to top
more

Owens & Minor (OMI)

(Delayed Data from NYSE)

$6.90 USD

6.90
1,285,114

+0.33 (5.02%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $6.90 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Earnings Preview: Owens & Minor (OMI) Q2 Earnings Expected to Decline

by Zacks Equity Research

Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Implied Volatility Surging for Owens & Minor (OMI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.

Zacks Equity Research

Owens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 24.68% and 3.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is GN Store Nord (GNNDY) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up

by Zacks Equity Research

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.

Zacks Equity Research

Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

In Q1, Chemed's (CHE) VITAS revenue decline was primarily the result of a 4.1% decline in days of care.

Zacks Equity Research

Earnings Preview: Owens & Minor (OMI) Q1 Earnings Expected to Decline

by Zacks Equity Research

Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Philips' (PHG) Q1 Earnings Down Y/Y on Supply Chain Constraints

by Zacks Equity Research

Koninklijke Philips' (PHG) Q1 top- and bottom-line results reflect negative impact of supply chain constraints and consequences of the Respironics field action.

Zacks Equity Research

Here's Why You Should Retain Integra (IART) Stock For Now

by Zacks Equity Research

Investors are optimistic about Integra (IART), given the strength in its CSS arm and notable product launches.

Zacks Equity Research

Here's Why You Should Hold on to Illumina (ILMN) Stock For Now

by Zacks Equity Research

Investors are optimistic about Illumina's (ILMN) strategic collaborations and strong international sales.

Zacks Equity Research

Patterson Companies (PDCO) Moves Up 12.5%: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Patterson Companies' (PDCO) robust segmental performance and strong prospects in the dental space.

Zacks Equity Research

Here's Why You Should Retain Zimmer Biomet (ZBH) Stock For Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) given robust demand for its ROSA robotics line and continued investment in profitable business areas.

Zacks Equity Research

Here's Why You Should Hold on to Haemonetics (HAE) For Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.

Zacks Equity Research

Has Owens & Minor (OMI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Owens & Minor (OMI) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

Zacks Equity Research

Illumina (ILMN) Hurt by Rising Costs, Tough Competition

by Zacks Equity Research

Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.

Zacks Equity Research

NEOGEN (NEOG) Adds to Prozap Insect Control Product Line-up

by Zacks Equity Research

NEOGEN's (NEOG) latest Prozap Protectus Pour-On Insecticide- IGR product relieves cattle from infestations.

Zacks Equity Research

Here's Why You Should Hold on to Cardiovascular Systems (CSII)

by Zacks Equity Research

Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.

Zacks Equity Research

IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists

by Zacks Equity Research

IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.

Zacks Equity Research

Here's Why You Should Retain Thermo Fisher (TMO) For Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

Zacks Equity Research

Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space

by Zacks Equity Research

Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.

Zacks Equity Research

Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth

by Zacks Equity Research

In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.

Zacks Equity Research

STERIS (STE) Up 8% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental growth and noteworthy acquisitions in the healthcare and pharmaceutical spaces.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock For Now

by Zacks Equity Research

Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.

Zacks Equity Research

Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes

by Zacks Equity Research

Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.